PDS Biotechnology (NASDAQ:PDSB – Get Rating)‘s stock had its “buy” rating reaffirmed by equities researchers at Noble Financial in a research report issued on Thursday, MarketBeat reports. They presently have a $22.00 target price on the stock. Noble Financial’s target price suggests a potential upside of 382.46% from the stock’s current price.
Separately, StockNews.com upgraded shares of PDS Biotechnology to a “sell” rating in a report on Saturday, April 9th. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $17.00.
Shares of NASDAQ PDSB opened at $4.56 on Thursday. The company has a market cap of $129.74 million, a P/E ratio of -5.56 and a beta of 2.34. The firm’s fifty day moving average is $5.66 and its two-hundred day moving average is $7.26. PDS Biotechnology has a 52-week low of $3.47 and a 52-week high of $17.85.
PDS Biotechnology (NASDAQ:PDSB – Get Rating) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). During the same quarter in the prior year, the company posted ($0.14) EPS. As a group, equities analysts anticipate that PDS Biotechnology will post -0.98 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of PDS Biotechnology by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 1,093,885 shares of the company’s stock worth $6,771,000 after buying an additional 79,025 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of PDS Biotechnology by 49.5% during the 1st quarter. Renaissance Technologies LLC now owns 665,037 shares of the company’s stock worth $4,117,000 after purchasing an additional 220,300 shares during the period. Two Sigma Advisers LP purchased a new position in shares of PDS Biotechnology during the 3rd quarter worth about $7,128,000. BlackRock Inc. boosted its stake in shares of PDS Biotechnology by 1.0% during the 1st quarter. BlackRock Inc. now owns 435,604 shares of the company’s stock worth $2,697,000 after purchasing an additional 4,199 shares during the period. Finally, Two Sigma Investments LP boosted its stake in shares of PDS Biotechnology by 450.9% during the 3rd quarter. Two Sigma Investments LP now owns 380,742 shares of the company’s stock worth $5,673,000 after purchasing an additional 311,635 shares during the period. 20.94% of the stock is owned by institutional investors and hedge funds.
About PDS Biotechnology (Get Rating)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.
Receive News & Ratings for PDS Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PDS Biotechnology and related companies with MarketBeat.com’s FREE daily email newsletter.